GlassScriptPhysician profile
Matthew Alan Lamca
NPI 1346762325
$4,605.36
in general payments reported to CMS, 2019-2025
25 companies · $948 in 2025
The $948 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $582 · 2023: $1,220 · 2024: $1,613 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.61 |
| Education | $270.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $714.61 | 2021-2025 | Jublia, Siliq, Arazlo |
| Abbvie INC. | $702.31 | 2022-2025 | |
| Janssen Biotech, INC. | $469.90 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $354.20 | 2022-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $351.21 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $307.59 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $278.68 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $191.87 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Organon LLC | $190.54 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $170.11 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $146.58 | 2022-2024 | Ilumya |
| Leo Pharma INC. | $141.84 | 2024 | Adbry |
| Pfizer INC. | $116.64 | 2022-2024 | |
| Amgen INC. | $85.66 | 2024-2025 | Otezla, Otezla |
| Journey Medical Corporation | $76.75 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $69.40 | 2025 | Sofdra |
| Genzyme Corporation | $53.87 | 2022-2025 | |
| Mimedx Group, INC. | $42.11 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $30.79 | 2023 | |
| Mayne Pharma Commercial LLC | $29.83 | 2023-2025 | |
| Organogenesis INC. | $21.38 | 2025 | Puraply Wound Matrix |
| Verrica Pharmaceuticals INC. | $21.11 | 2024 | Ycanth |
| Ucb, INC. | $16.47 | 2025 | Bimzelx |
| Advanced Oxygen Therapy INC. | $12.08 | 2024 | Topical Oxygen Chamber For Extremities |
| Sensus Healthcare, INC. | $9.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lamca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.